CKClaes Hannibal Kiilerich

Claes Hannibal Kiilerich

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Claes Hannibal Kiilerich has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Verrucous carcinoma may imitate persistent plantar warts with false-negative biopsies

    by Claes Hannibal Kiilerich, Abdullah Maarouf, Rebekka Søgaard, Lene Birk-Sørensen

    This case report describes a 61-year-old man whose persistent plantar wart was ultimately diagnosed as verrucous carcinoma, a rare, well-differentiated form of squamous cell carcinoma. Initial biopsies were false-negative, but wide excision later confirmed malignancy. This case underscores the importance of trusting clinical judgement and ensuring early intervention for refractory lesions.

  • Open Access

    Beyond Aesthetics: The Impact of Facial Non-Melanoma Skin Cancer (NMSC) Surgery on Patient Quality of Life

    by Celine Lund-Nielsen Remvig, Nicolai Blom, Claes Hannibal Kiilerich, Frederik Penzien Mamsen, Hannah Trøstrup Pedersen

    Facial non-melanoma skin cancer (NMSC) is the most common skin malignancy and often requires excision with reconstruction. Oncological outcomes are favorable, but effects on aesthetics and psychosocial well-being are less defined. We examined whether recon-structive technique influences patient-reported outcomes one year after facial NMSC surgery. Methods: In a prospective cohort at Zealand University Hospital, Denmark, patients underwent facial excision closed by either direct suturing (DS) or flap surgery (FS). Outcomes were measured with the FACE-Q Skin Cancer module: satisfaction with appearance, scar perception, cancer-related anxiety, and quality of life. Results: Of 225 enrolled patients, 52 (23.1%) completed one-year follow-up (DS n=38; FS n=14). Mean scar satisfaction scores were 91/100 for DS and 71/100 for FS. Cancer-related anxiety was higher after FS versus DS (23 vs 14/100; p=0.005). Overall satisfaction with facial appearance did not differ significantly. Stratification suggested outcomes depended more on anatomical site than technique. A modest inverse correlation was observed between scar satisfaction and cancer worry (r=−0.34). Conclusions: Reconstructive technique influenced pa-tient-reported outcomes, with FS associated with lower scar satisfaction and greater cancer-related anxiety. Site effects were prominent: nasal defects—often requiring flaps—had the lowest satisfaction, whereas cheek and forehead procedures showed high satisfaction irrespective of closure method.

  • Open Access

    Correction: Cosmetic Breast Augmentation with Autologous Ex Vivo-Expanded Adipose-Derived Mesenchymal Stem/Stromal Cell (Stemform®)-Enriched Fat Grafts: A Study of the First Twenty-Two Real-World Patients

    by Frederik Penzien Wainer Mamsen, Anne Fischer-Nielsen, Jesper Dyrendom Svalgaard, Jesper Due Jensen, Bo Jønsson, Dominik Duscher, Josef Christensen, Michiel Van Leeuwen, Claes Hannibal Kiilerich, Laura Roider, et al.

  • Open Access

    Cosmetic Breast Augmentation with Autologous Ex Vivo-Expanded Adipose-Derived Mesenchymal Stem/Stromal Cell (Stemform®)-Enriched Fat Grafts: A Study of the First Twenty-Two Real-World Patients

    by Frederik Penzien Wainer Mamsen, Anne Fischer-Nielsen, Jesper Dyrendom Svalgaard, Jesper Due Jensen, Bo Jønsson, Dominik Duscher, Josef Christensen, Michiel Van Leeuwen, Claes Hannibal Kiilerich, Laura Roider, et al.

    Background: Fat grafting is commonly utilized in breast surgery, and since it was first described, clinicians and researchers have stridden towards improvement of graft retention. Current advancements include adding adipose-derived mesenchymal stem/stromal cells (MSC(AT)s), which have demonstrated promise for improved graft retention. Objectives: This study reports outcomes for the first twenty-two patients undergoing breast augmentation (Stemform BA) or artificial implant replacement (Stemform AIR) with MSC(AT)-enriched fat in a real-world setting. Methods: Autologous MSC(AT)s were isolated and expanded ex vivo, then mixed with lipoaspirate and injected as enriched fat for Stemform BA and AIR. The breast volume was measured preoperatively and at 3 and 12 months postoperative using a 3D Infinity Dual-Lens Camera and LifeVizApp software. Additionally, independent plastic surgeons evaluated clinical images, and patient satisfaction was obtained at equal time points. Results: Twenty-two patients were included. All completed 3 and 12 months clinical follow-up and 3 months volume measurements. Nineteen patients completed 12 months volume measurements. The median fat graft retention at 12 months was 95.7% (IQR = 82.44–103.12%) for Stemform BA patients and 113.0% (IQR = 94.8–131.2%) for Stemform AIR patients. The Stemform BA patients had a median breast enlargement of 172.0% (IQR = 156.7–241.0%). The implant replacement volume of Stemform AIR patients was 102% (IQR = 85.1–130.3%). The patient reported 92.8% and 100% would elect to repeat treatment if they had the opportunity for Stemform BA and Stemform AIR, respectively. Conclusion: Breast augmentation and breast implant replacement patients receiving ex vivo-expanded MSC(AT)-enriched fat grafts had high graft retention and patient satisfaction scores. The paper confirms the clinical efficacy of using ex vivo-expanded MSC(AT)s. Level of Evidence V This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.